Moleculin Q1: Cash $10.3M; MIRACLE trial 40% CRc; 45 subjects enrolled

Moleculin Biotech, Inc.

Cash and equivalents $10.3M as of March 31, 2026; R&D expense $5.4M (up $2.0M YoY) on MIRACLE trial costs.
MIRACLE Phase 2B/3 trial: first 45 subjects enrolled; blinded composite complete remission (CRc) rate of 40%.
First interim unblinding expected June 2026; 90th subject recruitment targeted for Q3 2026.
Completed Q1 2026 financings with ~$8.3M gross proceeds; runway extended into Q3 2026.
Expect to start pancreatic cancer trial in 2H 2026; aiming for rolling NDA submission for R/R AML in 2028.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Moleculin Biotech, Inc. reported financial results for first quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 15, 2026, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026 and recent operational highlights.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-017226

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.